Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.
Actively Recruiting
Researchers are evaluating the safety and performance of the ConvaVAC13 Ag Negative Pressure Wound Therapy System in treating chronic wounds, specifically focusing on Venous Leg Ulcers VLUs. Chronic wounds are those that heal slowly or not at all, causing pain and affecting daily life. VLUs are the most common chronic leg wounds, affecting about 1 in 100 people, and current treatments include wound cleaning, special dressings, compression therapy, and antimicrobial creams or dressings. This study aims to see if the ConvaVAC13 Ag system can improve healing outcomes for VLUs effectively and safely. The ConvaVAC13 Ag system is a device that uses negative pressure wound therapy NPWT combined with silver ions, which have antimicrobial properties. NPWT involves applying a sealed dressing connected to a vacuum pump that removes excess fluid, promotes tissue growth, and reduces bacteria in the wound. The study involves participants receiving treatment with this device on their VLUs. The system aims to support wound healing by removing harmful biofilms and promoting tissue repair. Participants will be involved in the study for at least 14 days, during which the main measurement is the percentage reduction in wound size at day 14. Researchers will monitor wound healing progress and safety throughout the treatment period. The study helps assess how well the device performs in managing VLUs, with evaluations of wound condition and patient outcomes. The total participation time may vary depending on individual wound response and healing progress.